<p>/PRNewswire/ -- Edgewise Therapeutics, Inc.（“Edgewise” 或 “公司”），（纳斯达克：EWTX），是一家领先的肌肉疾病生物制药公司，致力于开发用于肌肉萎缩症和严重心脏病的新型治疗药物，今天宣布在 2026 年 5 月 29 日，Edgewise 根据其 2024 年诱导股权激励计划（“诱导计划”）向 4 名新非执行员工授予了总计 74,000 股 Edgewise 普通股的诱导股票期权，以便于他们的入职。</p>
<p>每个诱导股票期权的行使价格为每股 34.16 美元，等于授予日期 Edgewise 普通股的收盘价，并将按以下方式归属：每名员工入职一周年时，受该诱导股票期权约束的 25% 股份将归属，之后每月归属额外的 1/48 股份，前提是员工继续服务。</p>
<p>每个诱导奖励均受诱导计划及相关协议形式的条款约束，并作为对这些员工进入 Edgewise 工作的诱导，符合纳斯达克上市规则 5635(c)(4)。</p>
<p><strong>关于 Edgewise Therapeutics</strong></p>
<p>Edgewise Therapeutics 是一家领先的肌肉疾病生物制药公司，致力于开发用于肌肉萎缩症和严重心脏病的新型治疗药物。公司在肌肉生理学方面的深厚专业知识正在推动新一代新型治疗药物的研发。Sevasemten 是一种口服给药的首创快速骨骼肌肌球蛋白抑制剂，目前正在贝克和杜氏肌营养不良症的后期临床试验中。EDG-7500 是一种新型心脏肌节调节剂，用于治疗症状性肥厚型心肌病，目前处于第二阶段临床开发中。EDG-15400 是一种新型心脏肌节调节剂，用于治疗心力衰竭，目前处于第一阶段临床开发中。Edgewise 的整个团队致力于我们的使命：改变受严重肌肉疾病影响的患者和家庭的生活。欲了解更多信息，请访问：edgewisetx.com 或在 LinkedIn 和 X 上关注我们。</p>
<p>本新闻稿包含指向不被视为纳入本新闻稿的超链接信息。</p>
<p>来源：Edgewise Therapeutics</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjAzJk5ld3NJdGVtSWQ9TEE3NTQyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDMxNjAxUFJfTkVXU19VU1BSX19fX19MQTc1NDI2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjAzJk5ld3NJdGVtSWQ9TEE3NTQyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDMxNjAxUFJfTkVXU19VU1BSX19fX19MQTc1NDI2"/></p>

EWTX

<p>Edgewise Therapeutics（纳斯达克代码：EWTX）宣布根据其 2024 年诱导股权激励计划向四名新非执行员工授予 74,000 股的股票期权。这些期权的价格为每股 34.16 美元，四年内逐步归属，从入职一年后开始。这些授予是根据纳斯达克上市规则 5635(c)(4) 作为对新员工的重要诱因</p>

<p>, /PRNewswire/ -- Edgewise Therapeutics, Inc. (&#34;Edgewise&#34; or the &#34;Company&#34;), (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on May 29, 2026, Edgewise granted inducement stock options to purchase a total of 74,000 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the &#34;Inducement Plan&#34;).</p>
<div class="lb-trans"><p>/PRNewswire/ -- Edgewise Therapeutics, Inc.（“Edgewise” 或 “公司”），（纳斯达克：EWTX），是一家领先的肌肉疾病生物制药公司，致力于开发用于肌肉萎缩症和严重心脏病的新型治疗药物，今天宣布在 2026 年 5 月 29 日，Edgewise 根据其 2024 年诱导股权激励计划（“诱导计划”）向 4 名新非执行员工授予了总计 74,000 股 Edgewise 普通股的诱导股票期权，以便于他们的入职。</p>
</div><p>Each inducement stock option has an exercise price of $34.16 per share, which is equal to the closing price of a share of Edgewise common stock on the grant date, and shall vest as follows: 25% of the shares subject to such inducement stock option shall vest on the one year anniversary of the start date of each employee, and an additional one forty-eighth (1/48th) of the shares subject to such inducement stock option shall vest monthly thereafter, subject to the employee's continued service.</p>
<div class="lb-trans"><p>每个诱导股票期权的行使价格为每股 34.16 美元，等于授予日期 Edgewise 普通股的收盘价，并将按以下方式归属：每名员工入职一周年时，受该诱导股票期权约束的 25% 股份将归属，之后每月归属额外的 1/48 股份，前提是员工继续服务。</p>
</div><p>Each inducement award is subject to the terms of the Inducement Plan and related forms of agreements, and were granted as inducements material to these employees to enter into employment with Edgewise in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
<div class="lb-trans"><p>每个诱导奖励均受诱导计划及相关协议形式的条款约束，并作为对这些员工进入 Edgewise 工作的诱导，符合纳斯达克上市规则 5635(c)(4)。</p>
</div><p><strong>About Edgewise Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Edgewise Therapeutics</strong></p>
</div><p>Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of symptomatic hypertrophic cardiomyopathy, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: edgewisetx.com or follow us on LinkedIn and X.</p>
<div class="lb-trans"><p>Edgewise Therapeutics 是一家领先的肌肉疾病生物制药公司，致力于开发用于肌肉萎缩症和严重心脏病的新型治疗药物。公司在肌肉生理学方面的深厚专业知识正在推动新一代新型治疗药物的研发。Sevasemten 是一种口服给药的首创快速骨骼肌肌球蛋白抑制剂，目前正在贝克和杜氏肌营养不良症的后期临床试验中。EDG-7500 是一种新型心脏肌节调节剂，用于治疗症状性肥厚型心肌病，目前处于第二阶段临床开发中。EDG-15400 是一种新型心脏肌节调节剂，用于治疗心力衰竭，目前处于第一阶段临床开发中。Edgewise 的整个团队致力于我们的使命：改变受严重肌肉疾病影响的患者和家庭的生活。欲了解更多信息，请访问：edgewisetx.com 或在 LinkedIn 和 X 上关注我们。</p>
</div><p>This press release contains hyperlinks to information that is not deemed to be incorporated by reference into this press release.</p>
<div class="lb-trans"><p>本新闻稿包含指向不被视为纳入本新闻稿的超链接信息。</p>
</div><p>SOURCE Edgewise Therapeutics</p>
<div class="lb-trans"><p>来源：Edgewise Therapeutics</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjAzJk5ld3NJdGVtSWQ9TEE3NTQyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDMxNjAxUFJfTkVXU19VU1BSX19fX19MQTc1NDI2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA75426&amp;Transmission_Id=202606031601PR_NEWS_USPR_____LA75426&amp;DateId=20260603"/></p>

16:01 ET Edgewise Therapeutics 报告根据纳斯达克上市规则允许的激励授予情况